Risk adapted post-transplant maintenance in multiple myeloma

Iuliana Vaxman, Morie Gertz

Research output: Contribution to journalReview article

Abstract

Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Areas covered: In this review, we have summarized the current data on maintenance therapy in newly diagnosed MM patients undergoing ASCT, focusing on bortezomib, thalidomide and lenalidomide as well as newer agents Expert opinion: Maintenance treatment has been shown to deepen and prolong responses and increase PFS and OS. Lenalidomide is approved for maintenance and guidelines recommend its use post ASCT. Ixazomib has recently been reported to improve PFS.

Original languageEnglish (US)
Pages (from-to)107-118
Number of pages12
JournalExpert Review of Hematology
Volume12
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Multiple Myeloma
Maintenance
Transplants
Therapeutics
Thalidomide
Expert Testimony
Stem Cell Transplantation
Guidelines
Survival

Keywords

  • bortezomib
  • lenalidomide
  • Maintenance therapy
  • multiple myeloma
  • risk-adapted
  • thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Risk adapted post-transplant maintenance in multiple myeloma. / Vaxman, Iuliana; Gertz, Morie.

In: Expert Review of Hematology, Vol. 12, No. 2, 01.02.2019, p. 107-118.

Research output: Contribution to journalReview article

@article{bed02708f4ee4e6d9c6431d4a5fd8b37,
title = "Risk adapted post-transplant maintenance in multiple myeloma",
abstract = "Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Areas covered: In this review, we have summarized the current data on maintenance therapy in newly diagnosed MM patients undergoing ASCT, focusing on bortezomib, thalidomide and lenalidomide as well as newer agents Expert opinion: Maintenance treatment has been shown to deepen and prolong responses and increase PFS and OS. Lenalidomide is approved for maintenance and guidelines recommend its use post ASCT. Ixazomib has recently been reported to improve PFS.",
keywords = "bortezomib, lenalidomide, Maintenance therapy, multiple myeloma, risk-adapted, thalidomide",
author = "Iuliana Vaxman and Morie Gertz",
year = "2019",
month = "2",
day = "1",
doi = "10.1080/17474086.2019.1576521",
language = "English (US)",
volume = "12",
pages = "107--118",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Risk adapted post-transplant maintenance in multiple myeloma

AU - Vaxman, Iuliana

AU - Gertz, Morie

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Areas covered: In this review, we have summarized the current data on maintenance therapy in newly diagnosed MM patients undergoing ASCT, focusing on bortezomib, thalidomide and lenalidomide as well as newer agents Expert opinion: Maintenance treatment has been shown to deepen and prolong responses and increase PFS and OS. Lenalidomide is approved for maintenance and guidelines recommend its use post ASCT. Ixazomib has recently been reported to improve PFS.

AB - Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Areas covered: In this review, we have summarized the current data on maintenance therapy in newly diagnosed MM patients undergoing ASCT, focusing on bortezomib, thalidomide and lenalidomide as well as newer agents Expert opinion: Maintenance treatment has been shown to deepen and prolong responses and increase PFS and OS. Lenalidomide is approved for maintenance and guidelines recommend its use post ASCT. Ixazomib has recently been reported to improve PFS.

KW - bortezomib

KW - lenalidomide

KW - Maintenance therapy

KW - multiple myeloma

KW - risk-adapted

KW - thalidomide

UR - http://www.scopus.com/inward/record.url?scp=85062079169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062079169&partnerID=8YFLogxK

U2 - 10.1080/17474086.2019.1576521

DO - 10.1080/17474086.2019.1576521

M3 - Review article

C2 - 30696304

AN - SCOPUS:85062079169

VL - 12

SP - 107

EP - 118

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 2

ER -